ARCHIVES

Tempero, Johnson To Lead ASCO

This article is from The Cancer Letter archive.

Vol. 29 No. 13 | March 28, 2003

Download PDF Visit The Full Archive

Related Articles

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

November 28, 2014

Majority Of U.S. Cancer Patients Receive High-Quality Care, ASCO Study Finds

July 29, 2005

DCE Advisers Okay Cooperative Agreements For Epidemiolgic Of Esophageal Cancers

March 29, 1991

Drug Development: Herceptin Associated with 15 Deaths, Genentech Says

May 12, 2000

Herberman: Progress Made To Stabilize NSABP

September 9, 1994

Yates Identifies “Probable”, “Potential” Core Grant Applicants

January 16, 1987